MAIA Biotechnology, Inc.
MAIARating Trend
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 10, 2026 | $-0.13 | $-0.11 | — | — |
| May 11, 2026 | $-0.14 | $-0.18 | — | — |
| Mar 23, 2026 | $-0.08 | $-0.13 | — | — |
| Nov 7, 2025 | $-0.27 | $-0.19 | — | — |
| Aug 11, 2025 | $-0.18 | $-0.24 | — | — |
| May 9, 2025 | $-0.16 | $-0.18 | — | — |
| Mar 21, 2025 | $-0.17 | $-0.20 | — | — |
| Nov 12, 2024 | $-0.11 | $-0.39 | — | — |
News
Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study
New York, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research.
Seth Fiegerman says Meta is moving aggressively into AI agents, with a new enterprise product that looks like a ‘Muse'-style assistant for workplace use. He notes that the company's push suggests the focus is shifting from building the underlying AI technology to packaging it into tools that connect with day-to-day work and personal applications.
THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that it has received regulatory approval by the Spanish Agency for Medicines and Medical Devices (AEMPS) and Portugal's National Authority of Medicines and Health Products (INFARMED) to begin screening patients for …
Strong pace of patient enrollment supports continued advancement toward regulatory milestones Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed 90.5% disease control rate (DCR) in heavily pretreated NSCLC CHICAGO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that enro…
Milestone follows FDA clearance of MAIA's amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies
CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock were acquired by Mr. Guerrero between August 20, 2026, and September 10…
PIMCO economist Tiffany Wilding said labor markets are no longer a major source of inflation pressure, pointing to broad measures of nominal wage inflation that have been decelerating. She argued that AI, demographic shifts, aging, and retirements are changing labor dynamics and keeping wage pressures modest.
Next-generation divalent agents show increased anticancer activity in preclinical in vitro and in vivo models CHICAGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced its presentation of a poster featuring its second-generation telomere-targeting anticancer drug candidates at the recent XXVI International Round Table on Nucleoside…
New York, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research.